TRIKAFTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trikafta, and what generic alternatives are available?
Trikafta is a drug marketed by Vertex Pharms Inc and is included in two NDAs. There are thirty-five patents protecting this drug.
The generic ingredient in TRIKAFTA is elexacaftor, ivacaftor, tezacaftor; ivacaftor. One supplier is listed for this compound. Additional details are available on the elexacaftor, ivacaftor, tezacaftor; ivacaftor profile page.
DrugPatentWatch® Generic Entry Outlook for Trikafta
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TRIKAFTA?
- What are the global sales for TRIKAFTA?
- What is Average Wholesale Price for TRIKAFTA?
Summary for TRIKAFTA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Prices: | Drug price information for TRIKAFTA |
| What excipients (inactive ingredients) are in TRIKAFTA? | TRIKAFTA excipients list |
| DailyMed Link: | TRIKAFTA at DailyMed |
US Patents and Regulatory Information for TRIKAFTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-002 | Apr 26, 2023 | RX | Yes | Yes | 8,410,274 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | 9,670,163 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-002 | Jun 8, 2021 | RX | Yes | No | 11,453,655 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
